Ownership history in MARSHALL WACE, LLP · 12 quarters on record
This page tracks every 13F SEC filing in which MARSHALL WACE, LLP reported a position in ADVERUM BIOTECHN (ADVM). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | REDUCED | 28,367 | -21,261 | -42.8% | 0.00% | $129K | — |
| 2025 Q2 | REDUCED | 49,628 | -48,399 | -49.4% | 0.00% | $107K | — |
| 2024 Q4 | ADDED | 98,027 | +55,130 | +128.5% | 0.00% | $458K | — |
| 2024 Q3 | REDUCED | 42,897 | -161,722 | -79.0% | 0.00% | $301K | — |
| 2024 Q2 | ADDED | 204,619 | +70,768 | +52.9% | 0.00% | $1.4M | — |
| 2024 Q1 | REDUCED | 133,851 | -103,480 | -43.6% | 0.00% | $1.9M | — |
| 2023 Q3 | REDUCED | 237,331 | -104,066 | -30.5% | 0.00% | $356K | — |
| 2022 Q4 | REDUCED | 341,397 | -164,340 | -32.5% | 0.00% | $198K | — |
| 2022 Q3 | ADDED | 505,737 | +299,715 | +145.5% | 0.00% | $481K | — |
| 2021 Q4 | REDUCED | 206,022 | -152,144 | -42.5% | 0.00% | $364K | — |
As of 2025 Q3 — sorted by position size